Flu Vaccine's hidden power: boosting nose immunity
NCT ID NCT06824779
First seen Jan 10, 2026 · Last updated Jun 22, 2026 · Updated 25 times
Summary
This study looks at how the flu vaccine changes immune cells in the nose, which is the main entry point for flu viruses. Researchers will collect samples from 30 healthy adults before and after vaccination to measure memory immune cells. The goal is to understand local protection better, which could lead to more effective vaccines in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FLU VACCINE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU de Saint-Etienne
Saint-Etienne, 42055, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Flu vaccine
What this could lead to
If successful, this could help design better flu vaccines that boost immunity right where the virus enters—the nose.
What could go wrong
This is a small, early-stage observational study with only 30 participants, so results may not apply broadly. It measures immune markers, not actual infection prevention.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.